RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy MK-1045 enters first human trial for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called MK-1045 (CN201) in about 100 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. MK-1045 is an immunotherapy designed to help the immune system fight the cancer. The main goals are to check …
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New Dual-Targeting CAR-T therapy shows promise for tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough cancers: experimental drug LP-284 enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called LP-284 in about 110 adults whose lymphomas or solid tumors have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug move…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Lantern Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Off-the-Shelf CAR-T cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new CAR-T therapy made from donor cells, so it's ready to use without waiting for a patient's own cells to be modified. It targets two proteins on cancer cells to lower the chance of the cancer coming back. About 178 adults with relapsed or refractory B-cell ly…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: AvenCell Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Engineered immune cells take on childhood blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo aims to tackle tough lymphomas
Disease control Recruiting nowThis phase II trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and ATRA (a vitamin A derivative)—in 24 adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. Participants…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New antibody drug YK012 takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for tough lymphomas? daily pill trial launches
Disease control Recruiting nowThis phase II trial tests the drug pemigatinib (Pemazyre) in 27 adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell and marginal zone lymphoma. Participants take one pill daily in 28-day cycles. The main goal is to see if the drug can shrink tum…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC